SCYNEXIS Completes Transfer of BREXAFEMME NDA to GSK; Receives $145.5M Milestones, Royalties upon Relaunch

SCYNEXIS has completed the transfer of the BREXAFEMME New Drug Application to GSK, paving the way for the relaunch of the drug for vulvovaginal candidiasis and refractory vulvovaginal candidiasis. Following relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones and royalties in the low to mid single digit range. The transfer enables GSK to initiate regulatory interactions with the FDA.